Fig. 1
Trends in proportion of new user episodes which were SGLT-2i by A country and B overall in 2012–2017 (pre-propensity matching). SGLT-2i sodium–glucose cotransporter-2 inhibitor
Fig. 1 | Cardiovascular Diabetology
Trends in proportion of new user episodes which were SGLT-2i by A country and B overall in 2012–2017 (pre-propensity matching). SGLT-2i sodium–glucose cotransporter-2 inhibitor
Cardiovascular Diabetology